DICER1 and pancreatic ductal adenocarcinoma: In the future, phosphorylated Dicer S1728/S1852 could indicate drug resistance in pancreatic ductal adenocarcinoma patients, allowing for appropriate adjuvant therapy based on the degree of its phosphorylation.